Drug news
CHMP recommends Senshio as a treatment for Vulvar and Vaginal Atrophy- Shionogi
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Senshio (ospemifene), 60 mg, Film-coated tablet, from Shionogi, intended for the treatment of moderate to severe symptomatic Vulvar and Vaginal Atrophy (VVA) in post-menopausal women who are not candidates for local vaginal oestrogen therapy.
Ospemifene was FDA approved in 2013 as Osphena.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins